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Previews(including the MeCP2 null) and human
postmortem brain tissue, it is clear that
synaptic circuits are abnormal, often
characterized by a weakening and/or
loss of synapses (Banerjee et al., 2012;
Guy et al., 2011). Could the resident
brain macrophage, microglia, contribute
to this abnormal brain wiring in Rett
Syndrome? This is particularly interesting
given the abnormalities observed in
phagocytic function and inflammatory
pathways inMeCP2-null microglia (Cronk
et al., 2015; Derecki et al., 2012). Under-
standing the contribution of this resident
tissue macrophage to synaptic circuit
development and maintenance in Rett
Syndrome will be important and impactful
(Figure 1).
In summary, the manuscript by Cronk
et al. offers important insights into the
broad range of effects MeCP2 can have
outside the context of the central nervous
system, a largely unexplored aspect of
Rett Syndrome. On a molecular level,
this is the first paper to demonstrate602 Immunity 42, April 21, 2015 ª2015 ElsevMeCP2-dependent regulation of macro-
phage gene expression. On a cellular
level, this paper is the first to demonstrate
that subsets of macrophage populations
are particularly vulnerable to loss of
MeCP2 early in disease progression,
data which might be important for identi-
fying mechanisms of Rett Syndrome
onset and developmental regression.
Taken together, this work is a beautiful
example of how the immune and nervous
systems are intimately associated,
sharing common molecular pathways
and potentially affecting the function of
one another in many dynamic ways. Deci-
phering how immune cells throughout our
body affect a devastating neurological
disorder, Rett Syndrome, will be critical
steps going forward.REFERENCES
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The organism needs to tailor the intestinal inflammatory response to pathogenic bacteria and to pathobionts
that are only occasionally pathogenic. In this issue of Immunity, Seo et al. (2015) show that the pathobiont
Proteus mirabilis induces NLRP3 inflammasome-dependent interleukin-1b (IL-1b) release from CCR2+
Ly6Chigh inflammatory monocytes.In the famous eponymous episode of Star
Trek, the captain of the ship is split into
two different people, one evil and the
other virtuous, implying that both good
and bad perpetually exist in all of us. Is it
the same truth for the gut microbes?
What does it mean to be a pathobiont?
Do we suspect them of ‘‘going off the
rails’’ at random and becoming vicious
pathogens, or is there a hidden logic to
that? It has been long suspected that bac-
terial environmental stimuli, conditioned
by the inflammatory and immunologicalstate of the host, are the primary trigger
of the transformation of a commensal
microbe into a pathogen, and the exam-
ples are numerous. In this issue of Immu-
nity, Seo et al. (2015) have added a new
ingredient into the mix.
They provide data supporting a model
in which the host largely ignores the toxins
of the known pathobiont P. mirabilis until,
in response to the induction of colitis by
dextran sulfate sodium (DSS) treatment,
blood inflammatory monocytes express-
ing the inflammasome NOD-like receptorprotein-3 (NLRP3) arrive at the site of
inflammation (Figure 1). P. mirabilis acti-
vates the inflammasome and directs
the secretion of the interleukin-b (IL-1b)
cytokine that is necessary for induction
of colitis. Several conflicting reports
have been previously published indicating
either a protective or pro-colitogenic role
of NLRP3 and IL-1. The authors now pro-
pose that this discrepancy is explained by
the variable presence of hemolysin hpmA
producing P. mirabilis in the microbial
community of the gut (Seo et al., 2015).
Figure 1. The Induction of IL-1b and IL-18 in Intestinal Mucosa in Response to Bacterial Strains Is Dependent on Different Types of
Inflammasomes and Producer Cells
IL-18 is primarily produced in epithelial cells following processing by NLRP6 or NLRP3 and favors epithelial cell repair by increasing availability of IL-22 produced by
lymphoid cells. NLRP6 and NLRP3 also increase mucus formation by goblets cells with a mechanism that it is at least in part dependent on IL-18. Bacteria might
reach myeloid cells in the lamina propria by different mechanisms, including transmucosal transport by dendritic cells or migration through the damaged epithelial
layer. S. enterica induces IL-1b by activating NLRC4 on resident macrophages while P. mirabilis expressing the HpmA hemolysin activates NLRP3 on CCR2+ in-
flammatory monocytes. Enterohemorrhagic E. coli expressing specific enterohemolysin activates the NLRP3 inflammasome particularly on human macrophages.
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PreviewsDSS-induced colitis is characterized
by a robust production of cytokines,
including IL-1b, tumor necrosis factor
(TNF), and IL-6, that was abolished in
mice treated with antibiotics. The obser-
vation that Casp1/, Pycard/, and
Nlrp3/micewere also resistant to colitis,
whereas Aim2/ and Nlrc4/ mice were
susceptible, confirmed the role of the
NLRP3 inflammasome in the induction of
colitis by DSS (Seo et al., 2015). Using
diphtheria toxin (DT)-dependent depletion
models along with monocyte transfers,
the authors found that IL-1bwas produced
by CD11b+ Ly6C+ inflammatory mono-
cytes recruited via CCR2 signaling (Seo
et al., 2015). The screening of a panel of
bacteria isolated from mouse feces for
their ability to induce production of IL-1b
protein by mouse monocytes identified
P. mirabilis as a potent inducer of IL-1bcomparable to the pathogen Salmonella
enterica (Seo et al., 2015). Although
P. mirabilis is present in the normal gut mi-
crobiota of mice and humans, it is also a
frequent infectiousagent of urogenital tract
in humans.P.mirabilis has beenpreviously
reported to spontaneously induce colitis in
wild-typemicewhenadded incombination
with another pathobiont, Klebsiella pneu-
moniae, to the components of the endoge-
nousgutmicrobiota (Garrett et al., 2010). In
the experimental conditions described by
Seo et al. (2015), colonization of germ-
free mice with only P. mirabilis alone did
not result in IL-1b production unless the
mice were previously treated with DSS.
Because only inflammatory monocytes,
but not resident phagocytes, express
NLRP3 and produce IL-1b, an inflamed
environment and monocyte recruitment is
needed to reveal inflammasome activationImmunityby P. mirabilis (Seo et al., 2015). Although
P. mirabilis and S. enterica induce similar
amounts of IL-1b,S. enterica is recognized
by the NLRC4 inflammasome that is con-
stitutively expressed on lamina-propria-
residentmacrophages.Thus, thepresence
of the pathogen S. enterica is rapidly
detected and induces an inflammatory
response in resident cells, whereas the
pathobiont P. mirabilis induces activation
of the inflammasome and production of
IL-1b only when its presence is associated
with a pathologic state of inflammation that
recruits inflammatory monocytes from the
blood.
Detailed investigation of the products of
virulence genes of P. mirabilis led the
authors to identify HpmA hemolysin as
required for activation of the NLRP3 in-
flammasome and production of IL-1b.
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Previewsproteins are known to activate the NLRP3
inflammasome. For example, the specific
enterohemolysin from enterohemorrhagic
Escherichia coli strains activates the
NLRP3 inflammasome in human macro-
phages (Cheng et al., 2015). The inability
of E. coli in the study by Seo et al. (2015)
to induce inflammasome activation might
be due to use of other E. coli strains or to a
different sensitivity of NLRP3 activation in
human and mouse macrophage (Cheng
et al., 2015).
The paper by Seo et al. (2015) focuses
on secretion of IL-1b; however, inflamma-
some activation induces the processing
of both pro-IL-1b and pro-IL-18. Although
the role of IL-1 in DSS-induced colitis
has been controversial (Bersudsky et al.,
2014), many recent studies have shown
that IL-18 has an important protective
role on the colonic mucosa and that
Il18/ mice unable to produce the cyto-
kine, as well as Il18r/ and Myd88/
mice, unable to respond to the cytokine,
showed enhanced susceptibility to DSS
and induce colitis and tumor promotion
(Salcedo et al., 2010). IL-18 is mostly pro-
duced by the intestinal epithelial cells and
protects the mucosa by increasing avail-
ability of IL-22 either by blocking the pro-
duction of IL-22 binding protein (IL-22BP)
in macrophages or by a positive feedback
mechanism by which IL-18 enhances
transcription of IL-22 in lymphocytic cells
that than augments IL-18 production in
epithelial cells (Huber et al., 2012; Mun˜oz
et al., 2015). IL-22 protects the intestinal
mucosa by activating epithelial cell pro-
liferation and repair and by inducing
the production of antibacterial peptides.
Although the role of NLRP3 in the produc-
tion of IL-18 and protection by DSS-
induced colitis has been controversial,
the NLRP6 inflammasome, expressed
primarily in intestinal epithelial cells
but also in myofibroblasts and possibly
in hematopoietic cells, has been demon-
strated to regulate IL-18 production
and protect from DSS-induced colitis.604 Immunity 42, April 21, 2015 ª2015 ElsevNLRP6 and NLRP3 also protect the mu-
cosa by increasing the production of
mucus by goblet cells with a mechanism
that has been reported in different models
to be either IL-18 dependent or indepen-
dent (Engler et al., 2015; Wlodarska
et al., 2014). The microbiota of Nlrp6/
mice shows an altered fecal microbiota
with expansion of the bacterial phyla
Bacteroidetes (Prevotellaceae) and TM7
(Elinav et al., 2011). Susceptibility to
DSS-induced colitis could be transferred
from Nlrp6/ mice to wild-type mice by
transfer of the microbiota during cross-
fostering or co-housing; however, the
role of the two expanded bacterial spe-
cies in colitis remains correlative. Thus,
the lack of IL-18 or the absence of the
NLRP6 inflammasome induce an alter-
ation in the composition of the gut
microbiota that, similarly to P. mirabilis,
can increase susceptibility to DSS colitis
but that, unlike the combination of
P. mirabilis and K. pneumoniae, does not
induce colitis in untreated mice.
The paper by Seo et al. (2015) presents
a mechanism by which the organism can
tailor the response to intrinsically patho-
genic bacteria and to pathobionts that
only occasionally are associated with pa-
thology. However, there are many major
discrepancies in the literature regarding
the role of IL-1 and NLRP3 in either
causing or protecting from DSS-induced
colitis. For example, it has been shown
that although IL-1a produced by epithelial
cells is pro-inflammatory, IL-1b produced
mainly by myeloid cells is protective in
DSS-induced colitis by promoting healing
and repair (Bersudsky et al., 2014). In
the case of IL-18, it has not been yet
determined whether its secretion always
has a protective effect on DSS-induced
colitis. Depending on the nature of the
producer cells, their localization in the
mucosa, the type of inflammasome that
is activated and the time of production
following induction of inflammation IL-18
might be protective or rather contributeier Inc.to the pathology according to the ex-
pected pro-inflammatory role of this cyto-
kine because of its role in induction of IFN-
g and other cytokines. Thus, mechanisms
explaining the reported different results
on the role of IL-1, IL-18, and NLRP3 in
the pathogenesis of DSS-induced colitis
other than the presence or not of inflam-
masome activating bacteria in the gut mi-
crobiota, as shown by Seo et al. (2015),
still remain to be identified.
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